From VivoSight owners, in their own words
We conduct in-depth feedback discussions with VivoSight owners to better understand how OCT is used in a research and clinical setting. Quotes shown here are taken directly from these conversations. Please note that, as an ethical company, researchers and clinicians are never paid or rewarded for their quotes.
We hope it provides a deeper understanding of using VivoSight, and the reassurance of hearing it directly from your colleagues:
Microneedles – Drug Delivery – Vaccine Development
“VivoSight OCT is essential for our microneedle research and for the development of related devices and applications. The ability to visualize polymeric microneedles in-vivo allows for measurement of the exact depth of penetration. Moreover, OCT allows us to monitor swelling and dissolution kinetics of biodegradable needles. It is an indispensable tool to advance and optimize MAP research and product development”.
Ryan F. Donnelly, PhD. School of Pharmacy, Queen’s University Belfast, UK
Skin Cancer – Mohs Micrographic Surgery – Dermatologic Research
“I have used VivoSight for many years and I find that it is an excellent, reliable and fast method to aid in our decision making and treatment planning. Visual assessment and dermoscopy are used first for screening, then followed by OCT in dermoscopically unclear lesions.
We use it for Mohs surgery, to map the hidden border prior to surgery and we have found that the average number of stages can be reduced.
Outside of using OCT every day as a crucial part of our dermatology clinic, it can also be really useful as a research tool for issues such as wound healing, skin ageing, inflammatory diseases and much more”.
Julia Welzel, MD. Chief of Dermatology and Allergology at Augsburg University Hospital, Germany
Basal Cell Carcinoma
“We have found VivoSight to be a useful technology in our BCC practice. This allows us to investigate pre- Mohs surgical sites to a depth of 1 mm, and provides us with details to a depth of 1 mm which is well beyond the limitations of the naked eye and the dermatoscope. Visualization of tumor subtype size and depth helps us with pretreatment planning and also in monitoring subsequent outcomes”.
Chris Zachary, MD. Chair – Department of Dermatology, University of California, Irvine, CA, USA
Scars – Proliferative Vascular Disease – Skin Cancer
“VivoSight will be the greatest addition to the laser clinician’s armamentarium against scars since the fractional ablative laser. Also, for proliferative vascular disease and non-melanoma skin cancer, VivoSight will advance management through better assessment capabilities. Knowing the depth of scars allows me to accurately set fractional laser treatment depth, and knowing vessel diameters allows me to more accurately apply the theory of Selective Photothermolysis to customize laser settings to vessel thermal relaxation time. “
Jill Waibel, MD. Miami Institute of Dermatology, Miami, FL, USA
“I find the VivoSight system amazing for triaging BCC patients, for mapping the hidden tumor border and also for follow up after treatment to be sure the tumor has not returned. More effective triage with VivoSight means using OCT to assess whether a lesion is superficial, and if so, then I can confidently decide to do Aldara or cryotherapy for example , and if it is not, then we may operate. We can do diagnosis with dermoscopy but we are a lot more confident when we have the additional imaging from OCT.”